Protein Degradation & Targeting Undruggables Europe 2023

Facilitate successful clinical translation of PROTACs and Molecular Glues by expanding target classes and the ligase landscape through rational discovery & design paradigms beyond oncology

Download the agenda
Basel, Switzerland
19-20 September, 2023

“A lot of data on PROTAC research has been disclosed at this event. And also, many leaders in PROTACs shared their experience and concerns about their development. Many start-up companies also delivered their progress. We are able to discuss future directions as well as difficulties with experts from both industry and the academic area and learned a lot.”

Yuqing Huang Suzhou, Kintor Pharmaceuticals

Welcome to Protein Degradation & Targeting Undruggables European Congress Europe

The Congress returns to bring together leading experts and researchers from the field of targeted protein degradation and beyond to explore the latest advancements and therapeutic opportunities supporting successful clinical translation of candidates.

There is an emerging message that stemming from the success of occupancy driven pharmacology in the clinic and the opportunities unfolding from the event driven pharmacology space with promise to unlock the undruggable space further. However, challenges remain and will be addressed in this meeting in areas such as finding new E3 ligases and ligands, rational discovery and characterization of molecular glues, optimized PROTAC safety and PK/PD, and induced proximity concepts and therapeutic applicability.

Coupled with opportunities to elevate the quality of discussions and networking opportunities through our workshops, challenge roundtables and investor perspectives, the 5th Annual Protein Degradation & Targeting Undruggables Congress: Europe provides an unmissable experience towards optimising your research outcomes, pipeline viability and therapeutic success across diverse indications.

2023 Speakers

 

Markus Queisser

Scientific Leader, Protein Degradation DPU, R&D Future Pipelines Discovery
GSK

Markus Queisser

Scientific Leader, Protein Degradation DPU, R&D Future Pipelines Discovery
GSK

Markus Queisser

Scientific Leader, Protein Degradation DPU, R&D Future Pipelines Discovery
GSK
 

Natasa Zamurovic

Executive Director, TA Head Immunology, Preclinical Safety
Novartis

Natasa Zamurovic

Executive Director, TA Head Immunology, Preclinical Safety
Novartis

Natasa Zamurovic

Executive Director, TA Head Immunology, Preclinical Safety
Novartis
 

Graham Simpson

Senior Vice President, Drug Discovery
Dunad Therapeutics

Graham Simpson

Senior Vice President, Drug Discovery
Dunad Therapeutics

Graham Simpson

Senior Vice President, Drug Discovery
Dunad Therapeutics
 

Andreas Reichel

VP, Head of DMPK, Modelling & Simulations
Bayer

Andreas Reichel

VP, Head of DMPK, Modelling & Simulations
Bayer

Andreas Reichel

VP, Head of DMPK, Modelling & Simulations
Bayer
 

Gwenn Hansen

Chief Scientific Officer
Nurix Therapeutics

Gwenn Hansen

Chief Scientific Officer
Nurix Therapeutics

Gwenn Hansen

Chief Scientific Officer
Nurix Therapeutics
 

Brad Enerson

Executive Director, Head of Preclinical Safety
Kymera Therapeutics

Brad Enerson

Executive Director, Head of Preclinical Safety
Kymera Therapeutics

Brad Enerson

Executive Director, Head of Preclinical Safety
Kymera Therapeutics
 

Luc Brunsveld

Co-Founder, Professor, Chemical Biology
Ambagon Therapeutics/ Eindhoven University of Technology

Luc Brunsveld

Co-Founder, Professor, Chemical Biology
Ambagon Therapeutics/ Eindhoven University of Technology

Luc Brunsveld

Co-Founder, Professor, Chemical Biology
Ambagon Therapeutics/ Eindhoven University of Technology
 

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

Manfred Koegl is a director in Oncology Research in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. Presently, his team focuses on targeted protein degradation in cancer cell signaling.

Before 2010, he worked at the German Cancer Research Center in Heidelberg, Germany. He has worked at several small biotech companies in Heidelberg, including Phenex Pharmaceuticals. Manfred Koegl studied biology in Vienna and received his PhD in cell biology in 1994 at the EMBL, Heidelberg.

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

Manfred Koegl is a director in Oncology Research in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. Presently, his team focuses on targeted protein degradation in cancer cell signaling.

Before 2010, he worked at the German Cancer Research Center in Heidelberg, Germany. He has worked at several small biotech companies in Heidelberg, including Phenex Pharmaceuticals. Manfred Koegl studied biology in Vienna and received his PhD in cell biology in 1994 at the EMBL, Heidelberg.

 

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis
 

Adam Gilbert

Executive Director, External Accelerator
Pfizer

Adam Gilbert

Executive Director, External Accelerator
Pfizer

Adam Gilbert

Executive Director, External Accelerator
Pfizer
 

Kevin Moreau

Director, Safety Innovation and PROTAC Science Lead
AstraZeneca

Kevin Moreau

Director, Safety Innovation and PROTAC Science Lead
AstraZeneca

Kevin Moreau

Director, Safety Innovation and PROTAC Science Lead
AstraZeneca
 

Mary Matyskiela

VP, Molecular Sciences and Lead Discovery
Neomorph

Mary Matyskiela

VP, Molecular Sciences and Lead Discovery
Neomorph

Mary Matyskiela

VP, Molecular Sciences and Lead Discovery
Neomorph
 

Ted Suh

VP, Chemistry
Orionis Biosciences

Ted Suh

VP, Chemistry
Orionis Biosciences

Ted Suh

VP, Chemistry
Orionis Biosciences
 

Michael Plewe

SVP, Medicinal Chemistry
Cullgen

Michael Plewe is SVP - Medicinal Chemistry at Cullgen Inc., a company dedicated to the development of novel E3 ligands for targeted protein degradation in oncology and immune disease. Before joining Cullgen in 2018, he was the Head of Chemistry at Arisan Therapeutics, a start-up focused on developing novel treatments for neglected viral diseases. Prior to Arisan, he was an Associate Research Fellow and project leader at Pfizer Inc. working in multiple therapeutic areas including oncology, ophthalmology, diabetes, and infectious diseases such as HIV.

Michael Plewe

SVP, Medicinal Chemistry
Cullgen

Michael Plewe

SVP, Medicinal Chemistry
Cullgen

Michael Plewe is SVP - Medicinal Chemistry at Cullgen Inc., a company dedicated to the development of novel E3 ligands for targeted protein degradation in oncology and immune disease. Before joining Cullgen in 2018, he was the Head of Chemistry at Arisan Therapeutics, a start-up focused on developing novel treatments for neglected viral diseases. Prior to Arisan, he was an Associate Research Fellow and project leader at Pfizer Inc. working in multiple therapeutic areas including oncology, ophthalmology, diabetes, and infectious diseases such as HIV. He was a medicinal chemist at Agouron and at Vical, a gene therapy company. Dr. Plewe completed his postdoctoral training at the University of California at Irvine and earned his Ph. D. and Diploma in organic chemistry from the University of Konstanz in Germany.

 

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics
 

Hyunsun Jo

CEO
Pin Therapeutics

Dr. Hyunsun Jo is an entrepreneur in the biopharmaceutical industry. He is currently a Founder and Chief Executive Officer at Pin Therapeutics, which is located in South San Francisco and South Korea. Pin Therapeutics is backed by many venture capitals in South Korea and actively developing integrative drug discovery platform at the field of protein degradation therapeutics using small molecules. Prior to founding Pin Therapeutics, Dr. Jo has founded two biotech companies called by a LabQnA and an Embedbio.

Hyunsun Jo

CEO
Pin Therapeutics

Hyunsun Jo

CEO
Pin Therapeutics

Dr. Hyunsun Jo is an entrepreneur in the biopharmaceutical industry. He is currently a Founder and Chief Executive Officer at Pin Therapeutics, which is located in South San Francisco and South Korea. Pin Therapeutics is backed by many venture capitals in South Korea and actively developing integrative drug discovery platform at the field of protein degradation therapeutics using small molecules. Prior to founding Pin Therapeutics, Dr. Jo has founded two biotech companies called by a LabQnA and an Embedbio. He obtained his BA and PhD in Molecular Biology (Metabolic Diseases) at Seoul National University and Postdoc (aging-related diseases) at the Gladstone Institute (UCSF).

 

Giovanni Spagnolli

Co-founder, Chief Technology Officer
Sibylla Biotech

Giovanni Spagnolli

Co-founder, Chief Technology Officer
Sibylla Biotech

Giovanni Spagnolli

Co-founder, Chief Technology Officer
Sibylla Biotech
 

Matthias Brand

Co-Founder & CSO
Proxygen

Matthias Brand

Co-Founder & CSO
Proxygen

Matthias Brand

Co-Founder & CSO
Proxygen
 

Nicki Thompson

Chief Executive Officer
Amphista Therapeutics

Nicki Thompson

Chief Executive Officer
Amphista Therapeutics

Nicki Thompson

Chief Executive Officer
Amphista Therapeutics
 

Ryoma Hara

Principal Scientist, Chemistry
FIMECS

Ryoma Hara

Principal Scientist, Chemistry
FIMECS

Ryoma Hara

Principal Scientist, Chemistry
FIMECS
 

Ian Churcher

CSO
Amphista Therapeutics

Ian Churcher

CSO
Amphista Therapeutics

Ian Churcher

CSO
Amphista Therapeutics
 

Marcus Hartmann

Project Group Leader, Facility Head
Max Planck Institute

Marcus Hartmann

Project Group Leader, Facility Head
Max Planck Institute

Marcus Hartmann

Project Group Leader, Facility Head
Max Planck Institute
 

Erin Dueber

Director, Biological Chemistry
Genentech

Erin Dueber

Director, Biological Chemistry
Genentech

Erin Dueber

Director, Biological Chemistry
Genentech
 

Merve Mutlu

Postdoctoral Scholar
Novartis

Merve Mutlu

Postdoctoral Scholar
Novartis

Merve Mutlu

Postdoctoral Scholar
Novartis
 

Heide Marika Düvel

DMPK Expert, Targeted Protein Degraders
Merck

Heide Marika Düvel

DMPK Expert, Targeted Protein Degraders
Merck

Heide Marika Düvel

DMPK Expert, Targeted Protein Degraders
Merck
 

Caroline Rynn

DMPK-PD Project Leader, Senior Principal Scientist
Roche

Caroline Rynn

DMPK-PD Project Leader, Senior Principal Scientist
Roche

Caroline Rynn

DMPK-PD Project Leader, Senior Principal Scientist
Roche
 

Martin Hemmerling

Principal Scientist
AstraZeneca

Martin Hemmerling

Principal Scientist
AstraZeneca

Martin Hemmerling

Principal Scientist
AstraZeneca
 

Jacob Aguirre

Postdoctoral Researcher
Friedrich Miescher Institute

Jacob Aguirre

Postdoctoral Researcher
Friedrich Miescher Institute

Jacob Aguirre

Postdoctoral Researcher
Friedrich Miescher Institute
 

Benedict Cross

Chief Technology Officer
Phoremost

Benedict Cross

Chief Technology Officer
Phoremost

Benedict Cross

Chief Technology Officer
Phoremost
 

Fiona Sorrell

Principal Scientist, Medicinal Chemistry
Merck KGaA

Fiona Sorrell

Principal Scientist, Medicinal Chemistry
Merck KGaA

Fiona Sorrell

Principal Scientist, Medicinal Chemistry
Merck KGaA
 

Konstantinos Tzelepis

Principal Investigator
Wellcome-MRC Cambridge Stem Cell Institute/University of Cambridge

Konstantinos Tzelepis

Principal Investigator
Wellcome-MRC Cambridge Stem Cell Institute/University of Cambridge

Konstantinos Tzelepis

Principal Investigator
Wellcome-MRC Cambridge Stem Cell Institute/University of Cambridge
 

Dennis Gillingham

Professor
University of Basel

Dennis Gillingham

Professor
University of Basel

Dennis Gillingham

Professor
University of Basel

Previous Attendees Include

Delegate Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase after

— June 16, 2023 —

Friday, May 12, 2023 to Friday, June 16, 2023
Tier 1 - Academics
€899
Super Super Early Bird
Friday, May 12, 2023 to Saturday, June 17, 2023
Tier 2 - Biotechs & Pharma
€ 1,699
Super Super Early Bird
Thursday, March 30, 2023 to Wednesday, September 20, 2023
Tier 3 - Service Providers
€3599
Standard Price
Preparing registration...

Download the exclusive 2023 agenda

Download the agenda for the Protein Degradation & Targeting Undruggables Congress Europe 2023!


Download the agenda

Attendee Testimonials

2023 Partners

Platinum Sponsor

Silver Sponsors

Exhibitor

Media Partners

Become a partner

Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.

Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.

Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.

Find out more by calling us at +44 (0)20 3696 2920 or email Jack Tollervey at [email protected] 

Protein Degradation Media Kit

For more information on webinarsroundtablescontent marketing packagesinterviews and bespoke opportunities to accelerate Protein dedgradation innovation, download the Media Kit below.

DOWNLOAD THE MEDIA KIT

If you have any questions, please contact Simon Pickles, Senior Commercial Partnerships Manager, [email protected].

Poster Session

Looking to showcase your recent work to the protein degradation community?

Our dedicated poster session is the perfect way to get your research noticed. Ideal for PhD students or Post-Doctoral researchers.

In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. 

Applications closes 18 August 2023.

Abstracts received after this time may not be accepted so please submit your abstract here.

Kisaco Research will provide boards and fixings. Delegates are responsible for bringing the copy of their poster to be presented. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

Venue

Congress Center Basel Messeplatz. 21 4058, Basel

Congress Center Basel

Messeplatz. 21

4058, Basel

Resources

Download Resource

Highlights from previous years

Protein degradation Congress

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us